Eli Lilly (NYSE:LLY) touted data today from a Phase IIIb study of its once-weekly, injectable Type II diabetes medication, Trulicity.
The insulin-maker reported that its GLP-1 receptor agonist significantly improved blood sugar control in people with Type II diabetes when added to ongoing treatment with a SGLT-2 inhibitor.
Get the full story at our sister site, Drug Delivery Business News.